Maiwei Bio voluntarily discloses the announcement regarding the Phase III clinical trial of 9MW2821 for the treatment of cervical cancer, which has obtained approval from the Center for Drug Evaluation (CDE).

SZSI · Aug 23

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

迈威生物自愿披露关于9MW2821治疗宫颈癌的Ⅲ期临床研究获得CDE同意的公告

Maiwei Bio voluntarily discloses the announcement regarding the Phase III clinical trial of 9MW2821 for the treatment of cervical cancer, which has obtained approval from the Center for Drug Evaluation (CDE).

Risk Disclaimer

Statement